Paeoniflorin Attenuates the Progression of Diabetic Kidney Disease by Regulating Macrophage Differentiation
Phytotherapy Research · 2026-01 · 40 (1) · 213-226
DOI: 10.1002/ptr.70118 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytotherapy Research, online erschienen am 18.11.2025. Verfasst von Chunru Shi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Senior Department of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laborato…. Hauptthemen laut MEDLINE: Macrophages, Monoterpenes, Glucosides, Diabetic Nephropathies. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Natural Science Foundation of China, the Postdoctoral Fellowship Program of China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Paeoniflorin (PF), a bioactive compound from Paeonia lactiflora , exhibits anti‐inflammatory and immunomodulatory effects. Macrophage‐driven inflammation is a key contributor to diabetic kidney disease (DKD). This study aimed to determine whether PF mitigates DKD by regulating macrophage polarization. The db/db mice were treated orally with PF (50 or 100 mg/kg/day) for 10 weeks. Renal function, histopathology, and macrophage infiltration were assessed. In vitro, RAW264.7 macrophages were exposed to high glucose. Network pharmacology, molecular docking, cellular thermal shift assays (CETSA), and HIF‐1α siRNA knockdown were used to investigate mechanistic targets. PF improved renal function, reduced albuminuria, and attenuated glomerular injury. It decreased CD68 + macrophage infiltration and inhibited M1 polarization, lowering TNF‐α and iNOS expression. PF directly bound and stabilized HIF‐1α, while HIF‐1α knockdown abolished PF's anti‐inflammatory effects. PF reduced HIF‐1α protein expression without affecting mRNA expression, indicating post‐transcriptional regulation. PF protects against DKD by inhibiting HIF‐1α–mediated M1 macrophage polarization, revealing a novel mechanism to modulate macrophage‐driven renal inflammation and supporting PF as a potential therapeutic agent for DKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Senior Department of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Medical Devices and Integrated Traditional Chinese and Western D…
- The College of Traditional Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, China.
- College of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
ORCID-Profile: Chunru Shi, Guosen He
Förderung
- National Natural Science Foundation of China
- the Postdoctoral Fellowship Program of China Postdoctoral Science Foundation
Zitieren
APA
Shi, C., Li, R., Deng, L., Pan, D., Fu, Z., He, G., Qu, Y., Liu, R., Wang, X., Chen, X., & Hong, Q. (2026). Paeoniflorin Attenuates the Progression of Diabetic Kidney Disease by Regulating Macrophage Differentiation. Phytotherapy Research, 40(1), 213-226. https://doi.org/10.1002/ptr.70118
Vancouver
Shi C, Li R, Deng L, Pan D, Fu Z, He G, et al. Paeoniflorin Attenuates the Progression of Diabetic Kidney Disease by Regulating Macrophage Differentiation. Phytotherapy Research. 2026;40(1):213-226. doi:10.1002/ptr.70118
BibTeX
@article{Shi2026,
author = {Shi, Chunru and Li, Run and Deng, Lingchen and Pan, Dan and Fu, Zhangning and He, Guosen and Qu, Yilun and Liu, Ran and Wang, Xu and Chen, Xiangmei and Hong, Quan},
title = {Paeoniflorin Attenuates the Progression of Diabetic Kidney Disease by Regulating Macrophage Differentiation},
journal = {Phytotherapy Research},
year = {2026},
volume = {40},
number = {1},
pages = {213--226},
doi = {10.1002/ptr.70118}
}
EUVIMED